Fluoxetine (Synonyms: LY-110140 free base)

Name: Fluoxetine
Brand: MedChemExpress
SKU: HY-B0102
Rating: 5.0 (40 reviews)

Cat. No.: HY-B0102 Purity: 99.04%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Fluoxetine (LY-110140 free base) is a selective serotonin reuptake inhibitor (SSRI) class used for antidepressant research.

For research use only. We do not sell to patients.

CAS No. : 54910-89-3

Size	Stock	Quantity
Liquid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Liquid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	In-stock	Estimated Time of Arrival: December 31
1 g	Get quote
5 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 40 publication(s) in Google Scholar

Other Forms of Fluoxetine:

40 Publications Citing Use of MCE Fluoxetine

In Vivo Imaging

IHC

In Vivo Efficacy Study

: Fluoxetine purchased from MedChemExpress. Usage Cited in: Cell Metab. 2025 Dec 17:S1550-4131(25)00495-4. [Abstract]; Ovarian cancer ID8 syngeneic model testing fluoxetine effect, Fluoxetine treatment (20 mg/kg over drinking water starting 7 days before first chemotherapy and continued until harvest), Cisplatin (5 mg/kg, twice/week, intraperitoneal injection in indicated time windows). The figure shows representative bioluminescence imaging results.

: Fluoxetine purchased from MedChemExpress. Usage Cited in: Cell Metab. 2025 Dec 17:S1550-4131(25)00495-4. [Abstract]; Fluoxetine (20 mg/kg over drinking water starting 7 days before first chemotherapy and continued until harvest). Ovarian cancer PDX #1795 mouse model treated with PARPi (Olaparib) alone or with a combination of Fluoxetine.

: Fluoxetine purchased from MedChemExpress. Usage Cited in: Brain Behav Immun. 2021 Jul:95:142-153. [Abstract]; Fluoxetine (20 mg/kg; ip). Representative images of DCX positive cells in the DG of hippocampus in different group.

: Fluoxetine purchased from MedChemExpress. Usage Cited in: Brain Behav Immun. 2021 Jul:95:142-153. [Abstract]; Fluoxetine (20 mg/kg; ip). Representative immunoblots of DCX and NeuN expression levels in different groups.

: Fluoxetine purchased from MedChemExpress. Usage Cited in: Prog Neuropsychopharmacol Biol Psychiatry. 2017 Jun 15;79(Pt B):258-267. [Abstract]; Representative images showing the restoration effect of harmine on CUS-induced decrease in hippocampal DCX protein expressions. The Fluoxetine administration (20 mg/kg; ip) was used as a positive control, and all data were shown as mean ± SEM.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

Fluoxetine (LY-110140 free base) is a selective serotonin reuptake inhibitor (SSRI) class used for antidepressant research.

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	IC₅₀	13.1 μM Compound: 39	Inhibition of rat voltage-gated K channel 3.1 expressed in CHO cells by patch clamp assay Inhibition of rat voltage-gated K channel 3.1 expressed in CHO cells by patch clamp assay	[PMID: 23121096]
HEK293	EC₅₀	2.7 nM Compound: 2	Inhibition of human SERT-mediated serotonin reuptake in HEK293 cells Inhibition of human SERT-mediated serotonin reuptake in HEK293 cells	[PMID: 21927645]
HEK293	IC₅₀	1020 nM Compound: Fluoxetine	Inhibition of [3H]NE from human recombinant NET expressed in HEK293 cells Inhibition of [3H]NE from human recombinant NET expressed in HEK293 cells	[PMID: 19014888]
HEK293	IC₅₀	1020 nM Compound: Fluoxetine	Displacement of [3H]norepinephrine from human recombinant NET expressed in HEK293 cells by scintillation counting Displacement of [3H]norepinephrine from human recombinant NET expressed in HEK293 cells by scintillation counting	[PMID: 19256502]
HEK293	IC₅₀	14 μM Compound: 21	Inhibition of of human TREK1 expressed in HEK293 cells assessed as reduction in channel currents Inhibition of of human TREK1 expressed in HEK293 cells assessed as reduction in channel currents	[PMID: 26588045]
HEK293	IC₅₀	150 nM Compound: Fluoxetine	Inhibition of serotonin reuptake at human SERT expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay Inhibition of serotonin reuptake at human SERT expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay	[PMID: 24974340]
HEK293	IC₅₀	150 nM Compound: Fluoxetine	Inhibition of human SERT expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay Inhibition of human SERT expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay	[PMID: 25221656]
HEK293	IC₅₀	16 nM Compound: fluoxetine	Inhibition of [3H]5-HT uptake at 5HT transporter expressed in HEK293 cells Inhibition of [3H]5-HT uptake at 5HT transporter expressed in HEK293 cells	[PMID: 16750359]
HEK293	IC₅₀	16 nM Compound: fluoxetine	Inhibition of [3H]5-HT reuptake at 5HT transporter in HEK293 cells Inhibition of [3H]5-HT reuptake at 5HT transporter in HEK293 cells	[PMID: 16750363]
HEK293	IC₅₀	18400 nM Compound: Fluoxetine	Inhibition of DA reuptake at human DAT expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay Inhibition of DA reuptake at human DAT expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay	[PMID: 24974340]
HEK293	IC₅₀	18400 nM Compound: Fluoxetine	Inhibition of human DAT expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay Inhibition of human DAT expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay	[PMID: 25221656]
HEK293	IC₅₀	19500 nM Compound: Fluoxetine	Inhibition of [3H]DA from human recombinant DAT expressed in HEK293 cells Inhibition of [3H]DA from human recombinant DAT expressed in HEK293 cells	[PMID: 19014888]
HEK293	IC₅₀	19500 nM Compound: Fluoxetine	Displacement of [3H]dopamine from human recombinant DAT expressed in HEK293 cells by scintillation counting Displacement of [3H]dopamine from human recombinant DAT expressed in HEK293 cells by scintillation counting	[PMID: 19256502]
HEK293	IC₅₀	2.5 nM Compound: fluoxetine	Displacement of [I125]RTI-55 from human SERT transfected in human HEK293 cells Displacement of [I125]RTI-55 from human SERT transfected in human HEK293 cells	[PMID: 20034793]
HEK293	IC₅₀	2000 nM Compound: 3	Inhibition of norepinephrine uptake at human NET in human HEK293 cells Inhibition of norepinephrine uptake at human NET in human HEK293 cells	[PMID: 18550369]
HEK293	IC₅₀	2000 nM Compound: Fluoxetine	Inhibition of norepinephrine uptake at human NET expressed in HEK cells Inhibition of norepinephrine uptake at human NET expressed in HEK cells	[PMID: 18667309]
HEK293	IC₅₀	3.1 nM Compound: 2	Inhibition of serotonin reuptake at human SERT expressed in HEK293 cells Inhibition of serotonin reuptake at human SERT expressed in HEK293 cells	[PMID: 20724153]
HEK293	IC₅₀	3.1 μM Compound: Prozac	Displacement of [3H] astemizole from human recombinant ERG channel expressed in HEK293 cells Displacement of [3H] astemizole from human recombinant ERG channel expressed in HEK293 cells	[PMID: 20637635]
HEK293	IC₅₀	4400 nM Compound: fluoxetine	Inhibition of DA transporter expressed in HEK293 cells Inhibition of DA transporter expressed in HEK293 cells	[PMID: 16750359]
HEK293	IC₅₀	4400 nM Compound: fluoxetine	Inhibition of [3H]DA reuptake at DA transporter in HEK293 cells Inhibition of [3H]DA reuptake at DA transporter in HEK293 cells	[PMID: 16750363]
HEK293	IC₅₀	4410 nM Compound: Fluoxetine	Inhibition of norepinephrine reuptake at human NET expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay Inhibition of norepinephrine reuptake at human NET expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay	[PMID: 24974340]
HEK293	IC₅₀	4410 nM Compound: Fluoxetine	Inhibition of human NET expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay Inhibition of human NET expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay	[PMID: 25221656]
HEK293	IC₅₀	47 nM Compound: 3	Inhibition of serotonin uptake at human SERT in human HEK293 cells Inhibition of serotonin uptake at human SERT in human HEK293 cells	[PMID: 18550369]
HEK293	IC₅₀	47 nM Compound: Fluoxetine	Inhibition of serotonin uptake at human SERT expressed in HEK cells Inhibition of serotonin uptake at human SERT expressed in HEK cells	[PMID: 18667309]
HEK293	IC₅₀	5.2 nM Compound: Fluoxetine	Inhibition of [3H]serotonin reuptake at human SERT expressed in HEK293 cells by scintillation counting Inhibition of [3H]serotonin reuptake at human SERT expressed in HEK293 cells by scintillation counting	[PMID: 21093273]
HEK293	IC₅₀	5200 nM Compound: fluoxetine	Inhibition of [3H]NA uptake at NA transporter expressed in HEK293 cells Inhibition of [3H]NA uptake at NA transporter expressed in HEK293 cells	[PMID: 16750359]
HEK293	IC₅₀	5200 nM Compound: fluoxetine	Inhibition of [3H]NA reuptake at NA transporter in HEK293 cells Inhibition of [3H]NA reuptake at NA transporter in HEK293 cells	[PMID: 16750363]
HEK293	IC₅₀	6000 nM Compound: 3	Inhibition of dopamine uptake at human DAT in human HEK293 cells Inhibition of dopamine uptake at human DAT in human HEK293 cells	[PMID: 18550369]
HEK293	IC₅₀	6000 nM Compound: Fluoxetine	Inhibition of dopamine uptake at human DAT expressed in HEK cells Inhibition of dopamine uptake at human DAT expressed in HEK cells	[PMID: 18667309]
HEK293	IC₅₀	7 nM Compound: Fluoxetine	Inhibition of [3H]5HT from human recombinant SERT expressed in HEK293 cells Inhibition of [3H]5HT from human recombinant SERT expressed in HEK293 cells	[PMID: 19014888]
HEK293	IC₅₀	7.2 nM Compound: Fluoxetine, Prozac	Displacement of [3H]imipramin from human recombinant SERT over-expressed in HEK293 cells Displacement of [3H]imipramin from human recombinant SERT over-expressed in HEK293 cells	[PMID: 24012181]
HEK293	IC₅₀	7.3 nM Compound: Fluoxetine	Displacement of [3H]serotonin from human recombinant SERT expressed in HEK293 cells by scintillation counting Displacement of [3H]serotonin from human recombinant SERT expressed in HEK293 cells by scintillation counting	[PMID: 19256502]
HEK293	IC₅₀	8.6 nM Compound: fluoxetine	Displacement of [3H]Paroxetine from human recombinant SERT expressed in HEK293 cells after 60 mins Displacement of [3H]Paroxetine from human recombinant SERT expressed in HEK293 cells after 60 mins	[PMID: 23403082]
HeLa	IC₅₀	10 μM Compound: 33; MMV001561	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by resazurin dye based fluorescence assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by resazurin dye based fluorescence assay	[PMID: 30647879]
JAR	IC₅₀	10 nM Compound: 1	Inhibition of serotonin uptake at human SERT expressed in JAR cells Inhibition of serotonin uptake at human SERT expressed in JAR cells	[PMID: 18771916]
JAR	IC₅₀	10 nM Compound: 1	Inhibition of serotonin uptake at human SERT expressed in human JAR cells Inhibition of serotonin uptake at human SERT expressed in human JAR cells	[PMID: 19329313]
JAR	IC₅₀	32.4 nM Compound: fluoxetine	Inhibition concentration against [3H]5-HT uptake by human serotonin transporter in JAR cells Inhibition concentration against [3H]5-HT uptake by human serotonin transporter in JAR cells	[PMID: 15239661]
JAR	IC₅₀	39.4 nM Compound: fluoxetine	Inhibition of [3H]5-HT uptake at human 5-HT transporter expressed in Jar cells Inhibition of [3H]5-HT uptake at human 5-HT transporter expressed in Jar cells	[PMID: 16854086]
JAR	IC₅₀	39.4 nM Compound: fluoxetine	Inhibition of 5-HT transporter-mediated [3H]5HT uptake in human Jar cells Inhibition of 5-HT transporter-mediated [3H]5HT uptake in human Jar cells	[PMID: 18834188]
JAR	IC₅₀	9.4 nM Compound: 1	Inhibition of serotonin uptake at human SERT expressed in JAR cells Inhibition of serotonin uptake at human SERT expressed in JAR cells	[PMID: 18951020]
JAR	IC₅₀	9.4 nM Compound: Fluoxetine	Inhibition of human SERT expressed in JAR cells Inhibition of human SERT expressed in JAR cells	[PMID: 19713106]
JAR	IC₅₀	9.4 nM Compound: Fluoxetine	Inhibition of serotonin uptake at human SERT expressed in human JAR cells Inhibition of serotonin uptake at human SERT expressed in human JAR cells	[PMID: 20131864]
JAR	IC₅₀	9.4 nM Compound: Fluoxetine	Inhibition of human SERT expressed in human JAR cells Inhibition of human SERT expressed in human JAR cells	[PMID: 20378347]
JAR	IC₅₀	9.4 nM Compound: Fluoxetine	Inhibition of SERT-mediated serotonin uptake in human JAR cells Inhibition of SERT-mediated serotonin uptake in human JAR cells	[PMID: 20462211]
JAR	IC₅₀	9.4 nM Compound: Fluoxetine	Inhibition of human SERT expressed in JAR cells assessed as serotonin uptake Inhibition of human SERT expressed in JAR cells assessed as serotonin uptake	[PMID: 21916421]
JAR	IC₅₀	9.4 nM Compound: fluoxetine	Inhibition of 5HT uptake at human SERT expressed in human JAR cells Inhibition of 5HT uptake at human SERT expressed in human JAR cells	[PMID: 18557608]
JAR	IC₅₀	9.4 nM Compound: fluoxetine	Inhibition of serotonin uptake at human SERT expressed in JAR cells Inhibition of serotonin uptake at human SERT expressed in JAR cells	[PMID: 19632110]
JAR	IC₅₀	9.4 nM Compound: fluoxetine	Inhibition of [3H]hydroxytryptamine creatinine sulfate uptake at human SERT expressed in human JAR cells Inhibition of [3H]hydroxytryptamine creatinine sulfate uptake at human SERT expressed in human JAR cells	[PMID: 19722525]
K562	CC₅₀	25 μM Compound: 8	Cytotoxicity to reduce chronic myeloid leukemia K 562 cells Cytotoxicity to reduce chronic myeloid leukemia K 562 cells	[PMID: 15267229]
MCF7	IC₅₀	10 nM Compound: Fluoxetine	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth	[PMID: 32738968]
MDA-MB-231	IC₅₀	0.5 μM Compound: 41	Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 33650861]
MDA-MB-436	IC₅₀	0.5 μM Compound: 41	Anticancer activity against human MDA-MB-436 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Anticancer activity against human MDA-MB-436 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 33650861]
MDCK	IC₅₀	563 nM Compound: 1	Inhibition of norepinephrine uptake at human NET expressed in MDCK cells Inhibition of norepinephrine uptake at human NET expressed in MDCK cells	[PMID: 18771916]
RD	CC₅₀	11.9 μM Compound: Fluoxetine	Cytotoxicity against human RD cells after 3 days by neutral red dye-based photometric method Cytotoxicity against human RD cells after 3 days by neutral red dye-based photometric method	[PMID: 30912944]
U-937	CC₅₀	33.3 μM Compound: 8	Cytotoxicity to reduce human histolytic lymphoma U937 cells Cytotoxicity to reduce human histolytic lymphoma U937 cells	[PMID: 15267229]
Ventricular myocyte	IC₅₀	2.82 μM Compound: Fluoxetine	Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes	[PMID: 22761000]

In Vitro

Fluoxetine blocks the downregulation of cell proliferation resulting from inescapable shock (IS) of hippocampal cell^[1]. Fluoxetine increases the number of newborn cells in the dentate gyrus of the hippocampus of adult rat. Fluoxetine also increases the number of proliferating cells in the prelimbic cortex^[2]. Fluoxetine accelerates the maturation of immature neurons. Fluoxetine enhances neurogenesis-dependent long-term potentiation (LTP) in the dentate gyrus^[3]. Fluoxetine, but not citalopram, fluvoxamine, paroxetine and sertraline, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Fluoxetine produces robust and sustained increases in extracellular concentrations of norepinephrine and dopamine after acute systemic administration^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Fluoxetine treatment also reverses the deficit in escape latency observed in animals exposed to inescapable shock in adult male Sprague-Dawley rats^[1]. Fluoxetine (5 mg/kg) alone increases cell proliferation in the dentate gyrus. Coadministration (fluoxetine 5 mg/kg + olanzapine) also significantly increases the number of BrdU-positive cells compared with the control group^[2]. Fluoxetine combined with Olanzapine produces robust, sustained increases of extracellular levels of dopamine ([DA](ex)) and norepinephrine ([NE](ex)) up to 361% and 272% of the baseline, respectively, which are significantly greater than either drug alone^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

309.33

Formula

C₁₇H₁₈F₃NO

CAS No.

54910-89-3

Appearance

Liquid (Density: 1.159±0.06 g/cm³)

Color

Colorless to light yellow

SMILES

FC(C1=CC=C(OC(C2=CC=CC=C2)CCNC)C=C1)(F)F

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Pure form	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (323.28 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.2328 mL	16.1640 mL	32.3279 mL
5 mM	0.6466 mL	3.2328 mL	6.4656 mL
10 mM	0.3233 mL	1.6164 mL	3.2328 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (6.72 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (6.72 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (6.72 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC-Na/saline water
Solubility: 10 mg/mL (32.33 mM); Suspended solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.87%

Select Batch:

Data Sheet (278 KB) SDS (892 KB)

COA (246 KB) HNMR (254 KB) LCMS (261 KB)

Handling Instructions (2659 KB)

References

[1]. Malberg JE, et al. Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. Neuropsychopharmacology. 2003 Sep;28(9):1562-71 [Content Brief]

[2]. Avitsur R1. Increased symptoms of illness following prenatal stress: Can it be prevented by fluoxetine? Behav Brain Res. 2017 Jan 15;317:62-70. [Content Brief]

[3]. Kodama M, et al. Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol Psychiatry. 2004 Oct 15;56(8):570-80. [Content Brief]

[4]. Wang JW, et al. Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. J Neurosci. 2008 Feb 6;28(6):1374-84. [Content Brief]

[5]. Bymaster FP, et al. Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl). 2002 Apr;160(4):353-61 [Content Brief]

[6]. Zhang W, et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology. 2000 Sep;23(3):250-62. [Content Brief]

Animal Administration
^[2]

Male Sprague-Dawley rats weighing 250-300 g are housed under a 12-hour light/12-hour dark cycle (lights on at 7:00 am, lights off at 7:00 pm) and at constant temperature (25°C) and humidity and allowed free access to food and water. For chronic drug treatments, rats are administered fluoxetine (5 mg/kg/day) or saline by intraperitoneal (IP) injection once daily and olanzapine or vehicle in the drinking water for 21 days (vehicle-treated control, fluoxetine, and olanzapine alone) plus the combination of fluoxetine and olanzapine. For combination treatment, olanzapine is chosen because fluoxetine is known to interfere with the metabolism of olanzapine and raise the blood levels by up to 4-6 times. Olanzapine is dissolved in hydrochloric acid (HCl), then adjusted back to pH 6 with 1 N sodium hydroxide to make the stock solution of 3 mg/mL concentration. The same amount of vehicle solution is added to the water for the control animals. Fluid intake is measured three times per week, and drinking bottles are replenwashed with fresh drug solution. There are no differences in fluid intake among the treatment groups. For subchronic treatment, drugs are administered exactly the same way but for a total period of 7 days.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

[1]. Malberg JE, et al. Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. Neuropsychopharmacology. 2003 Sep;28(9):1562-71 [Content Brief]

[2]. Avitsur R1. Increased symptoms of illness following prenatal stress: Can it be prevented by fluoxetine? Behav Brain Res. 2017 Jan 15;317:62-70. [Content Brief]

[3]. Kodama M, et al. Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol Psychiatry. 2004 Oct 15;56(8):570-80. [Content Brief]

[4]. Wang JW, et al. Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. J Neurosci. 2008 Feb 6;28(6):1374-84. [Content Brief]

[5]. Bymaster FP, et al. Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl). 2002 Apr;160(4):353-61 [Content Brief]

[6]. Zhang W, et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology. 2000 Sep;23(3):250-62. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.2328 mL	16.1640 mL	32.3279 mL	80.8198 mL
	5 mM	0.6466 mL	3.2328 mL	6.4656 mL	16.1640 mL
	10 mM	0.3233 mL	1.6164 mL	3.2328 mL	8.0820 mL
	15 mM	0.2155 mL	1.0776 mL	2.1552 mL	5.3880 mL
	20 mM	0.1616 mL	0.8082 mL	1.6164 mL	4.0410 mL
	25 mM	0.1293 mL	0.6466 mL	1.2931 mL	3.2328 mL
	30 mM	0.1078 mL	0.5388 mL	1.0776 mL	2.6940 mL
	40 mM	0.0808 mL	0.4041 mL	0.8082 mL	2.0205 mL
	50 mM	0.0647 mL	0.3233 mL	0.6466 mL	1.6164 mL
	60 mM	0.0539 mL	0.2694 mL	0.5388 mL	1.3470 mL
	80 mM	0.0404 mL	0.2020 mL	0.4041 mL	1.0102 mL
	100 mM	0.0323 mL	0.1616 mL	0.3233 mL	0.8082 mL

Fluoxetine Related Classifications

Neurological Disease

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Fluoxetine54910-89-3LY-110140LY110140LY 110140Serotonin TransporterAutophagy5-HTTSERTSLC6A4Inhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Fluoxetine (Synonyms: LY-110140 free base)

Customer Review

Other Forms of Fluoxetine:

Fluoxetine Related Antibodies

40 Publications Citing Use of MCE Fluoxetine

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Fluoxetine Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Fluoxetine Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report